Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 20, 2024

Key Takeaways for Biosimilar Utilization

The panelists provide their closing thoughts, highlighting key considerations around biosimilar.

Episodes in this series

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

A panel of 4 experts on biosimilars

EP. 7 Private Label Biosimilars

EP. 8 Biosimilars in the Commercial Sector

EP. 8 Biosimilars in the Commercial Sector

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 11 Unmet Needs and Future Initiatives

EP. 11 Unmet Needs and Future Initiatives

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 13 Foreseeable Biosimilar Trends

EP. 13 Foreseeable Biosimilar Trends

EP. 14 Legislative Support for Biosimilars

EP. 14 Legislative Support for Biosimilars

EP. 15 Key Takeaways for Biosimilar Utilization

EP. 15 Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

Thanks to all of you for this rich and informative discussion. Before we conclude I’d like to get final thoughts from each of you…

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Investing in the Future: Redesigning Healthcare Infrastructure for CRM Excellence

ByIan J. Neeland, MD

June 16th 2026

Experts featured in this series.

Beyond the Prescription: Navigating Side Effects, Patient Agency, and Generic Variability

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 16th 2026 | Updated: June 16th 2026

Experts featured in this series.

From Uncertainty to Action: How Psychiatrists Navigate Complex Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 16th 2026 | Updated: June 16th 2026

From Reactive to Proactive: Evolving Health Systems for CRM Management

ByIan J. Neeland, MD

June 16th 2026

Experts featured in this series.

Provider Shortages and Diagnostic Complexity: The Compounding Challenges of Mental Health Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 15th 2026 | Updated: June 15th 2026

Trending on AJMC

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer

Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL

Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD

Gene Therapy Reduces LV Mass in Friedreich Ataxia Cardiomyopathy